Authors

  • Юнусова Л.Р.
  • Бойкобилова С.Ж.
  • Янгибаев Ж.С.

References

1. Shu-Chun Chuang, Carlo La Vecchia, Paolo Boffetta, Liver cancer: Descriptive epidemiology and risk factors other than HBV and HCV infection,Cancer Letters,Volume 286, Issue 1,2009,Pages 9-14, https://doi.org/10.1016/j.canlet.2008.10.040.

2. Ruben R. Plentz, Nisar P. Malek, Clinical presentation, risk factors and staging systems of cholangiocarcinoma,Best Practice & Research Clinical Gastroenterology,Volume 29, Issue 2,2015,Pages 245-252, https://doi.org/10.1016/j.bpg.2015.02.00

3. Aparna Schweitzer, Johannes Horn, Rafael T Mikolajczyk, Gérard Krause, Jördis J Ott, Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013, The Lancet, Volume 386, Issue 10003, 2015, Pages 1546-1555, https://doi.org/ 10.1016/S0140-6736(15)61412-X.

4. Justin R. Bailey, Eleanor Barnes, Andrea L. Cox, Approaches, Progress, and Challenges to Hepatitis C Vaccine Development, Gastroenterology, Volume 156, Issue 2, 2019,Pages 418-430, https:// doi.org/10.1053/j.gastro.2018.08.060.

5. Jonathan H Williams, Timothy D Phillips, Pauline E Jolly, Jonathan K Stiles, Curtis M Jolly, Deepak Aggarwal, Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions2, The American Journal of Clinical Nutrition, Volume 80, Issue 5, 2004,Pages 1106-1122,ISSN 0002-9165,https://doi. org/10.1093/ajcn/80.5.1106.

6. Harriet Rumgay, Jacques Ferlay, Catherine de Martel, Damien Georges, Amal Samy Ibrahim, Rongshou Zheng, Wenqiang Wei, Valery E.P.P. Lemmens, Isabelle Soerjomataram, Global, regional and national burden of primary liver cancer by subtype, European Journal of Cancer, Volume 161, 2022, Pages 108-118, https://doi.org/10.1016/j.ejca.20 21.11.023.

7. Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest 2012;122:2911–2915.

8. Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notchmediated conversion of hepatocytes. J Clin Invest 2012;122:3914–3918.

9. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004;4: 695–706.

10. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2011;8:512–522.

11. Yang JD, Kim B, Sanderson SO, Sauver JS, Yawn BP, Larson JJ, et al. Biliary tract cancers in Olmsted County, Minnesota, 1976–2008. Am J Gastroenterol 2012;107:1256–1262.

12. Bragazzi MC, Carpino G, Venere R, Semeraro R, Gentile R, et al. Cholangiocarcinoma: epidemiology and risk factors. Translational Gastrointestinal Cancer 2012;1:21–32.

13. Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford) 2008;10:77–82.

14. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004;24:115–125.

15. Shaib YH, Davila JA, McGlynn K, El-Serag HB. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol 2004;40:472–477.

16. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 2001; 48:816–820.

17. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001;33:1353–1357.

18. West J, Wood H, Logan RF, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer 2006;94:1751–1758.

19. Alvaro D, Crocetti E, Ferretti S, Bragazzi MC, Capocaccia R. Descriptive epidemiology of cholangiocarcinoma in Italy. Dig Liver Dis 2010;42: 490–495.

20. von Hahn T, Ciesek S, Wegener G, Plentz RR, Weismuller TJ, Wedemeyer H, et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol 2011; 46:1092–1098.

21. Shin HR, Oh JK, Lim MK, Shin A, Kong HJ, Jung KW, et al. Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea. J Korean Med Sci 2010;25:1011–1016.

22. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002;37:806–813.

23. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002; 2:10.

24. Jepsen P, Vilstrup H, Tarone RE, Friis S, Sorensen HT. Incidence rates of intra- and extrahepatic cholangiocarcinomas in Denmark from 1978 through 2002. J Natl Cancer Inst 2007;99:895–897.

25. Tyson GL, El-Serag HB. Risk factors for cholangiocarcinoma. Hepatology 2011;54:173–184.

26. McLean L, Patel T. Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int 2006;26: 1047–1053.

27. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15: 1198–1203.

28. Khan SA, Emadossadaty S, Ladep NG, Thomas HC, Elliott P, Taylor-Robinson SD, et al. Rising trends in cholangiocarcinoma: is the ICD classification system misleading us? J Hepatol 2012;56: 848–854.

29. Nakeeb A, Pitt HA, Sohn TA, Coleman J, Abrams RA, Piantadosi S, et al. Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–473, [discussion 47 3–465].

30. DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007;245:755–762.

31. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005;366: 1303–1314.

32. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 2013;144:829–840.

33. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013;32: 4861–4870

34. Marahatta SB, Punyarit P, Bhudisawasdi V, Paupairoj A, Wongkham S, Petmitr S. Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett 2006;236:276–281.

35. Hoblinger A, Grunhage F, Sauerbruch T, Lammert F. Association of the c.3972C>T variant of the multidrug resistance-associated protein 2 Gene (MRP2/ABCC2) with susceptibility to bile duct cancer. Digestion 2009;80: 36–39.

36. Wadsworth CA, Dixon PH, Wong JH, Chapman MH, McKay SC, Sharif A, et al. Genetic factors in the pathogenesis of cholangiocarcinoma. Dig Dis 2011;29:93–97. Melum E, Karlsen TH, Schrumpf E, Bergquist A, Thorsby E, Boberg KM, et al. Cholangiocarcinoma in primary sclerosing cholangitis is associated with NKG2D polymorphisms. Hepatology 2008;47:90–96.

37. Huang WY, Gao YT, Rashid A, Sakoda LC, Deng J, Shen MC, et al. Selected base excision repair gene polymorphisms and susceptibility to biliary tract cancer and biliary stones: a population-based case-control study in China. Carcinogenesis 2008; 29:100–105.

38. Sakoda LC, Gao YT, Chen BE, Chen J, Rosenberg PS, Rashid A, et al. Prostaglandin-endoperoxide synthase 2 (PTGS2) gene polymorphisms and risk of biliary tract cancer and gallstones: a population-based study in Shanghai, China. Carcinogenesis 2006;27:1251–1256.

39. Mihalache F, Hoblinger A, Grunhage F, Krawczyk M, Gartner BC, Acalovschi M, et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. Aliment Pharmacol Ther 2011;33: 389–394.

40. Sia D, Hoshida Y, Villanueva A, Roayaie S, Ferrer J, Tabak B, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology 20 13;144:829–840.

41. Sia D, Tovar V, Moeini A, Llovet JM. Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene 2013;32: 4861–4870.

42. Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, et al. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology 2012;142:e1015.

43. Andersen JB, Thorgeirsson SS. Genetic profiling of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2012;28:266–272.

44. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2010;70:3034–3041.

45. Oishi N, Kumar MR, Roessler S, Ji J, Forgues M, Budhu A, et al. Transcriptomic profiling reveals hepatic stem-like gene signatures and interplay of miR-200c and epithelial-mesenchymal transition in intrahepatic cholangiocarcinoma. Hepatology 2012;56:1792–1803.

46. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779–6788.

47. Tannapfel A, Benicke M, Katalinic A, Uhlmann D, Kockerling F, Hauss J, et al. Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 20 00;47:721–727.

48. Voss JS, Holtegaard LM, Kerr SE, Fritcher EG, Roberts LR, Gores GJ, et al. Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013;44 :1216–1222.

49. O’Dell MR, Huang JL, Whitney-Miller CL, Deshpande V, Rothberg P, Grose V, et al. Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma. Cancer Res 2012;72:1557–1567.

50. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J Clin Oncol 2010;28:3531–3540.

51. Farazi PA, Zeisberg M, Glickman J, Zhang Y, Kalluri R, DePinho RA. Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. Cancer Res 2006;66: 6622–6627.

52. Tannapfel A, Sommerer F, Benicke M, Katalinic A, Uhlmann D, Witzigmann H, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003;52:706–712.

53. Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012;17:72–79.

54. Wang P, Dong Q, Zhang C, Kuan PF, Liu Y, Jeck WR, et al. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas. Oncogene 2013;32:3091–3100.

55. Ong CK, Subimerb C, Pairojkul C, Wongkham S, Cutcutache I, Yu W, et al. Exome sequencing of liver fluke-associated cholangiocarcinoma. Nat Genet 2012;44:690–693.

56. Koo SH, Ihm CH, Kwon KC, Park JW, Kim JM, Kong G. Genetic alterations in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Genet Cytogenet 2001;130:22–28.

57. Wong N, Li L, Tsang K, Lai PB, To KF, Johnson PJ. Frequent loss of chromosome 3p and hypermethylation of RASSF1A in cholangiocarcinoma. J Hepatol 2002;37:633–639.

58. Uhm KO, Park YN, Lee JY, Yoon DS, Park SH. Chromosomal imbalances in Korean intrahepatic cholangiocarcinoma by comparative genomic hybridization. Cancer Genet Cytogenet 2005;157:37–41.

59. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, et al. Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol 2009;40:834–842.

60. Lee JY, Park YN, Uhm KO, Park SY, Park SH. Genetic alterations in intrahepatic cholangiocarcinoma as revealed by degenerate oligonucleotide primed PCR-comparative genomic hybridization. J Korean Med Sci 2004;19:682–687.

61. Wu YM, Su F, Kalyana-Sundaram S, Khazanov N, Ateeq B, Cao X, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov 2013;3:636–647.

62. Arai Y, Totoki Y, Hosoda F, Shirota T, Hama N, Nakamura H, et al. FGFR2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2013. http://dx.doi.org/10.1002/ hep.26890.

63. Chen L, Yan HX, Yang W, Hu L, Yu LX, Liu Q, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol 2009;50:358–369.

64. Tannapfel A, Sommerer F, Benicke M, Weinans L, Katalinic A, Geissler F, et al. Genetic and epigenetic alterations of the INK4a-ARF pathway in cholangiocarcinoma. J Pathol 2002;197:624–631.

65. Isomoto H, Mott JL, Kobayashi S, Werneburg NW, Bronk SF, Haan S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007;132: 384–396.

66. Tischoff I, Markwarth A, Witzigmann H, Uhlmann D, Hauss J, Mirmohammadsadegh A, et al. Allele loss and epigenetic inactivation of 3p21.3 in malignant liver tumors. Int J Cancer 2005;115:684–689.

67. Chan-On W, Nairismagi ML, Ong CK, Lim WK, Dima S, Pairojkul C, et al. Exome sequencing identifies distinct mutational patterns in liver flukerelated and non-infection-related bile duct cancers. Nat Genet 2013;45:1474–1478.

68. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013;45:1470–1473.

69. Park J, Tadlock L, Gores GJ, Patel T. Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology 1999;30: 1128–1133.

70. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, et al. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005;42:1329–1338.

71. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Aktsignaling pathway in cholangiocarcinoma cells. Gastroenterology 2005;128:2054–2065.

72. Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008;98: 418–425.

73. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology 2002;36:439–450. [92] Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and cmet in biliary tract cancers. J Pathol 2005;206:356–365.

74. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of MET overexpression in human intrahepatic cholangiocarcinoma and in hepatolithiasis. Hum Pathol 1998;29:175–180.

75. Hamilton S. Pathology and genetics of tumours of the digestive system. Lyon: IARC Press; 2000.

76. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010;2:419–427.

77. Nakajima T, Kondo Y, Miyazaki M, Okui K. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol 1988;19:1228–1234.

78. Nakanuma Y, Harada K, Ishikawa A, Zen Y, Sasaki M. Anatomic and molecular pathology of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2003;10:265–281. [106] Nakanuma Y, Sasaki M, Ikeda H, Sato Y, Zen Y, Kosaka K, et al. Pathology of peripheral intrahepatic cholangiocarcinoma with reference to tumorigenesis. Hepatol Res 2008;38:325–334.

79. Nakanuma Y, Xu J, Harada K, Sato Y, Sasaki M, Ikeda H, et al. Pathological spectrum of intrahepatic cholangiocarcinoma arising in non-biliary chronic advanced liver diseases. Pathol Int 2011;61:298–305.

80. Vilana R, Forner A, Bianchi L, Garcia-Criado A, Rimola J, de Lope CR, et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 2010;51:2020–2029.

81. Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology 2009;50:791–798.

82. Goodman ZD. Neoplasms of the liver. Mod Pathol 2007;20:S49–S60. [111] Cabibi D, Licata A, Barresi E, Craxi A, Aragona F. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol Res Pract 2003;199:65–7

83. Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J, Bioulac-Sage P. Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol 2000;24:870–876.

84. Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ. The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000;95: 204–207.

85. Tamandl D, Herberger B, Gruenberger B, Puhalla H, Klinger M, Gruenberger T. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008;15:2787–2794.

86. Uenishi T, Yamazaki O, Tanaka H, Takemura S, Yamamoto T, Tanaka S, et al. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008;15:583–589.

87. Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D. Expression of microRNAs, miR-21, miR-31, miR-122, miR145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013;52:297–303.

88. Nishino R, Honda M, Yamashita T, Takatori H, Minato H, Zen Y, et al. Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma. J Hepatol 2008;49:207–216.

89. Schmitz KJ, Lang H, Frey UH, Sotiropoulos GC, Wohlschlaeger J, Reis H, et al. GNAS1 T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 2007;9:159–165.

90. Hann LE, Schwartz LH, Panicek DM, Bach AM, Fong Y, Blumgart LH. Tumor involvement in hepatic veins: comparison of MR imaging and US for preoperative assessment. Radiology 1998;206:651–656.

91. Bach AM, Hann LE, Brown KT, Getrajdman GI, Herman SK, Fong Y, et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996;201:149–154.

92. Corvera CU, Blumgart LH, Akhurst T, DeMatteo RP, D’Angelica M, Fong Y, et al. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008;206:57–65.

93. Kim JY, Kim MH, Lee TY, Hwang CY, Kim JS, Yun SC, et al. Clinical role of 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008;103:1145–1151.

94. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002;87:13–15.

95. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474. [138] Tsai S, Nathan H, Pawlik TM. Primary liver cancer: intrahepatic cholangiocarcinoma emerges from the shadows. Updates Surg 2010;62:5–9.

96. Nathan H, Pawlik TM. Staging of intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2010;26:269–273.

97. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003;10:288–291.

98. Okabayashi T, Yamamoto J, Kosuge T, Shimada K, Yamasaki S, Takayama T, et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001;92:2374–2383.

99. [142] Nathan H, Aloia TA, Vauthey JN, Abdalla EK, Zhu AX, Schulick RD, et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009;16:14–22.

100. Farges O, Fuks D, Le Treut YP, Azoulay D, Laurent A, Bachellier P, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer 2011;117:2170–2177.

101. Fadahunsi O.O., Ibitoye B.O., Adisa A.O., Alatise O.I., Adetiloye V.A., Idowu B.M. Diagnostic accuracy of ultrasonography in adults with obstructive jaundice. J. Ultrason. 2020;20:e100–e105. doi: 10.15 557/JoU.2020.0016.

102. Sharma M.P., Ahuja V. Aetiological spectrum of obstructive jaundice and diagnostic ability of ultrasonography: A clinician’s perspective. Trop. Gastroenterol. 1999;20:167–169.

103. Bloom C.M., Langer B., Wilson S.R. Role of US in the detection, charac-terization, and staging of cholangiocarcinoma. Radiographics. 1999;19:1199–1218. doi: 10.1148/radiographics.19.5.g99se0811 99.

104. Saini S. Imaging of the Hepatobiliary Tract. N. Engl. J. Med. 1997;336:1889–1894. doi: 10.1056/NEJM199706263362607.

105. Razumilava N., Gores G.J., Lindor K.D. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54:1842–1852. doi: 10.1002/hep.24570.

106. Valls C., Gumà A., Puig I., Sanchez A., Andía E., Serrano T., Figueras J. Intrahepatic peripheral cholangiocarcinoma: CT evaluation. Abdom. Imaging. 2000;25:490–496. doi: 10.1007/s002610000 079.

107. Choi S.H., Han J.K., Lee J.M., Lee K.H., Kim S.H., Lee J.Y., Choi B.I. Differentiating Malignant from Benign Common Bile Duct Stricture with Multiphasic Helical CT. Radiology. 2005;236:178–183. doi: 10.1148/radiol.2361040792.

108. Iavarone M., Piscaglia F., Vavassori S., Galassi M., Sangiovanni A., Venerandi L., Forzenigo L.V., Golfieri R., Bolondi L., Colombo M. Contrast enhanced CT-scan to diagnose intrahepatic chol-angiocarcinoma in patients with cirrhosis. J. Hepatol. 2013;58:1188–1193. doi: 10.1016/j.jhep.2013.02.0

109. Kim S.A., Lee J.M., Lee K.B., Kim S.H., Yoon S.H., Han J.K., Choi B.I. Intrahepatic mass-forming cholangiocarcinomas: Enhancement patterns at multiphasic CT, with special emphasis on arterial enhancement pattern--correlation with clinicopathologic findings. Radiology. 2011;260:148–157. doi: 10.1148/radiol.11101777.

110. Fowler K.J., Sheybani A., Parker R.A., 3rd, Doherty S., Brunt E.M., Chapman W.C., Menias C.O. Combined hepatocellular and cholangiocarcinoma (biphenotypic) tumors: Imaging features and diagnostic accuracy of contrast-enhanced CT and MRI. AJR Am. J. Roentgenol. 2013;201:332–339. doi: 10.2214/AJR.12.9488.

111. Sanada Y., Shiozaki S., Aoki H., Takakura N., Yoshida K., Yamaguchi Y. A clinical study of 11 cases of combined hepatocellular-cholangiocarcinoma Assessment of enhancement patterns on dynamics computed tomography before resection. Hepatol. Res. 2005;32:185–195. doi: 10.1016/j. hepres.2005.04.003.

112. Manfredi R., Barbaro B., Masselli G., Vecchioli A., Marano P. Magnetic resonance imaging of cholangiocarcinoma. Semin. Liver Dis. 2004;24:155–164. doi: 10.1055/s-2004-828892.

113. Potretzke T.A., Tan B.R., Doyle M.B., Brunt E.M., Heiken J.P., Fowler K.J. Imaging Features of Biphenotypic Primary Liver Carcinoma (Hepatocholangiocarcinoma) and the Potential to Mimic Hepatocellular Carcinoma: LI-RADS Analysis of CT and MRI Features in 61 Cases. AJR Am. J. Roentgenol. 2016;207:25–31. doi: 10.2214/AJR.15.14997.

114. Hwang J., Kim Y.K., Park M.J., Lee M.H., Kim S.H., Lee W.J., Rhim H.C. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI. J. Magn. Reason. Imaging. 2012;36:881–889. doi: 10.1002/jmri.237 28.

115. Chong Y.S., Kim Y.K., Lee M.W., Kim S.H., Lee W.J., Rhim H.C., Lee S.J. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using gadoxetic acid-enhanced MRI. Clin. Radiol. 2012;67:766–773. doi: 10.1016/j.crad.2012.01.004.

116. Zidi S.H., Prat F., Le Guen O., Rondeau Y., Pelletier G. Performance characteristics of magnetic resonance cholangiography in the staging of malignant hilar strictures. Gut. 2000;46:103–106. doi: 10.1136/gut.46.1.103.

117. Lee M.G., Park K.B., Shin Y.M., Yoon H.K., Sung K.B., Kim M.H., Lee S.G., Kang E.M. Preoperative evaluation of hilar cholangiocarcinoma with contrast-enhanced three-dimensional fast imaging with steady-state precession magnetic resonance angiography: Comparison with intraarterial digital subtraction angiography. World J. Surg. 2003;27:278–283. doi: 10.1007/s00268-002-6701-1.

118. Park H.S., Lee J.M., Choi J.Y., Lee M.W., Kim H.J., Han J.K., Choi B.I. Preoperative evaluation of bile duct cancer: MRI combined with MR cholangiopancreatography versus MDCT with direct cholangiography. AJR Am. J. Roentgenol. 2008;190:396–405. doi: 10.2214/AJR.07.2310.

119. Rösch T., Meining A., Frühmorgen S., Zillinger C., Schusdziarra V., Hellerhoff K., Classen M., Helmberger H. A prospective comparison of the diagnostic accuracy of ERCP, MRCP, CT, and EUS in biliary strictures. Gastrointest. Endosc. 2002;55:870–876. doi: 10.1067/mge.2002.124206.

120. Yeh T.S., Jan Y.Y., Tseng J.H., Chiu C.T., Chen T.C., Hwang T.L., Chen M.F. Malignant perihilar biliary obstruction: Magnetic resonance cholangiopancreatographic findings. Am. J. Gastroenterol. 2000;95:432–440. doi: 10.1111/j.1572-0241.2000. 01763.x.

121. Freeman M.L., Sielaff T.D. A modern approach to malignant hilar biliary obstruction. Rev. Gastroenterol. Disord. 2003;3:187–201.

122. Corvera C.U., Blumgart L.H., Akhurst T., DeMatteo R.P., D’Angelica M., Fong Y., Jarnagin W.R. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J. Am. Coll. Surg. 2008;206:57–65. doi: 10.1016/j.jamcollsurg.2007.07.002.

123. Kim Y.J., Yun M., Lee W.J., Kim K.S., Lee J.D. Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur. J. Nucl. Med. Mol. Imaging. 2003;30:1467–1472. doi: 10.1007/s00259-003-12 97-8.

124. Li J., Kuehl H., Grabellus F., Müller S.P., Radunz S., Antoch G., Nadalin S., Broelsch C.E., Gerken G., Paul A., et al. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J. Surg Oncol. 2008;98:438–443. doi: 10.1002/jso.211 36.

125. Alkhawaldeh K., Faltten S., Biersack H.J., Ezziddin S. The value of F-18 FDG PET in patients with primary sclerosing cholangitis and cholangiocarcinoma using visual and semiquantitative analysis. Clin. Nucl. Med. 2011;36:879–883. doi: 10.1097/ RLU.0b013e3182291a64.

126. Nishiyama Y., Yamamoto Y., Kimura N., Miki A., Sasakawa Y., Wakabayashi H., Ohkawa M. Comparison of early and delayed FDG PET for evaluation of biliary stricture. Nucl. Med. Commun. 2007;28:914–919. doi: 10.1097/MNM.0b013e3282f 1ac85.

127. National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology. [(accessed on 18 May 2022)]. Available online: https://www.nccn.org/professionals/physician_gls

128. Shin DW, Moon SH, Kim JH. Diagnosis of Cholangiocarcinoma. Diagnostics (Basel). 2023 Jan 8;13(2):233. doi: 10.3390/diagnostics13020233.